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Abstract  1 
Myeloid derived suppressor cells (MDSCs) are an immunosuppressive 2 
population of immature myeloid cells found in advanced stage cancer patients 3 
and mouse tumor models.  Production of inducible nitric oxide synthase (iNOS) 4 
and arginase, as well as other suppressive mechanisms, allow MDSCs to 5 
suppress T cell-mediated tumor clearance and foster tumor progression. Using 6 
an unbiased global gene expression approach in conditional p120-catenin 7 
knockout mice (L2-cre;p120ctnf/f), a model of oral-esophageal cancer, we have 8 
identified CD38 as playing a vital role in MDSC biology, previously 9 
unknown.  CD38 belongs to the ADP-ribosyl cyclase family and possesses both 10 
ectoenzyme and receptor functions.  It has been described to function in 11 
lymphoid and early myeloid cell differentiation, cell activation and neutrophil 12 
chemotaxis.  We find that CD38 expression in MDSCs is evident in other mouse 13 
tumor models of esophageal carcinogenesis, and CD38high MDSCs are more 14 
immature than MDSCs lacking CD38 expression, suggesting a potential role for 15 
CD38 in the maturation halt found in MDSC populations.  CD38high MDSCs also 16 
possess a greater capacity to suppress activated T cells, and promote tumor 17 
growth to a greater degree than CD38low MDSCs, likely as a result of increased 18 
iNOS production. Additionally, we have identified novel tumor-derived factors, 19 
specifically IL-6, IGFBP-3 and CXCL16, which induce CD38 expression by 20 
MDSCs ex vivo. Finally, we have detected an expansion of CD38-positive 21 
MDSCs in peripheral blood of advanced stage cancer patients and validated 22 
targeting CD38 in vivo as a novel approach to cancer therapy.  23 
 4 
Introduction 1 
The immune system (both innate and adaptive) plays an essential role in 2 
limiting tumor growth, and therefore, tumor progression requires escape from 3 
immune surveillance.  One mechanism that allows for tumor escape is the 4 
activation and expansion of immunosuppressive cell populations, including but 5 
not limited to, regulatory T cells (Tregs) and myeloid derived suppressor cells 6 
(MDSCs) (1), the latter also referred to as immature myeloid cells (IMCs). Certain 7 
therapeutics have demonstrated potential efficacy against MDSCs (2); however, 8 
the need for more selective anti-MDSC therapeutics remains. 9 
 MDSCs have been observed in a number of mouse tumor models and 10 
represent a heterogeneous population of immature monocytes and granulocytes 11 
that are identified by their CD11b+Gr1+ phenotype in mice (3). In human disease, 12 
the first immature myeloid cell population with immunosuppressive capacity was 13 
described in head and neck cancer (4), and since then MDSCs have been 14 
documented in cancers of the esophagus, stomach, pancreas, lung, kidney, 15 
colon, skin, prostate, and breast (5–10). The immunophenotype of human 16 
MDSCs varies (11), however, their immunosuppressive mechanisms match 17 
those found in murine CD11b+Gr1+ MDSC populations.   18 
MDSCs induce immune suppression primarily through inhibition of T cell-19 
mediated tumor clearance (3), but can also promote inhibition of NK cells (12) 20 
and activation of Tregs (13).  Arginase-1 (ARG1) and inducible nitric oxide 21 
synthase-2 (iNOS) provide the bulk of the enzymatic activity required for MDSCs 22 
to suppress T cell proliferation and activation of (3). ARG1 deprives T cells of 23 
 5 
arginine by converting L-arginine into urea and L-ornithine, thereby reducing 1 
expression of CD3ζ chain, which renders T cells unable to respond to activation 2 
signals (14).  iNOS inhibits T cell function by a variety of mechanisms, including 3 
inhibition of JAK3/STAT5 signaling (15), MHC Class II expression (16) and 4 
induction of apoptosis (17).   5 
 CD38 expression is a common characteristic to several 6 
immunosuppressive cell types.  Foxp3+CD25+CD4+ Tregs expressing high CD38 7 
levels possess a greater immunosuppressive activity than CD38low Tregs (18). 8 
CD38+CD8+ T cells suppress proliferation of CD4+ effector T cells, which requires 9 
IFNγ secretion and cell-to-cell contact (19).  Similarly, CD19+CD24hiCD38hi B 10 
cells inhibit differentiation of T helper 1 cells in an IL-10 dependent manner, and 11 
their dysfunction may play a role in autoimmune disorders such as systemic 12 
lupus erythematosus (20).  13 
CD38 is a member of the ribosyl cyclase family and is expressed on the 14 
surface of diverse immune cells, including B cells, T cells, NK cells and myeloid 15 
cells (21).  CD38 possesses independent ectoenzyme and receptor functions.  16 
As an ectozyme, CD38 catalyzes synthesis and hydrolysis of cyclic ADP-ribose 17 
(cADPR), converting NAD+ to ADP-ribose (ADPR), as well as cADPR into ADPR 18 
(21,22). Furthermore, at acidic pH, CD38 catalyzes synthesis and hydrolysis of 19 
nicotinic acid adenine dinucleotide phosphate (NAADP) (21,22). Both reactions 20 
are essential for calcium signaling, specifically for mobilization of intracellular 21 
Ca2+ (22). Receptor activity of CD38 has been documented in multiple immune 22 
cell types, where it is dependent on localization to the lipid rafts and association 23 
 6 
with professional signaling complexes (21). In both mouse and human myeloid 1 
cells, ligation of CD38 receptor leads to suppressed growth and survival resulting 2 
in loss of the most differentiated immune populations (23). 3 
In this study we have identified CD38 as a novel marker for MDSCs that 4 
possess greater immunosuppressive capacity, thereby promoting tumor growth 5 
in vivo.   We have identified a mechanistic role for CD38 in promoting expansion 6 
of the monocytic MDSC population, as well as in regulating expression of the 7 
effector molecule iNOS by these cells. Additionally, we have established for the 8 
first time that several cytokines, specifically IFN, TNFα, IGFBP-3, CXCL16 and 9 
IL-6, are capable of inducing CD38 expression in MDSCs. Finally, we have 10 
demonstrated that administration of an anti-CD38 monoclonal antibody slows 11 
disease progression in tumor-bearing mice. As we have detected an expansion 12 
of CD38-positive MDSC-like population in peripheral blood of advanced-stage 13 
cancer patients, this study introduces the concept of anti-CD38 monoclonal 14 
antibody therapy for potential treatment of certain solid tumors. 15 
  16 
 7 
Materials and Methods 1 
Generation of MDSCs 2 
All animal studies were approved by the Institutional Animal Care and Use 3 
Committee (IACUC) at the University of Pennsylvania. Mice were housed under 4 
a 12-hour light/dark cycle and fed ad libitum. We have described the L2-5 
Cre;p120ctnf/f mouse model of oral-esophageal cancer previously (24). We also 6 
used syngeneic subcutaneous transplantation models utilizing the HNM007 and 7 
AKR ESCC cell lines in either C57BL/6J (Jackson Labs) or Cd38-/- mice (gift from 8 
Dr. Eduardo Chini). For generation of MDSCs, L2-Cre;p120ctnf/f mice were aged 9 
until signs of preneoplasia and neoplasia were evident; subcutaneous tumor-10 
bearing mice were aged until tumors reached a volume of 0.8cm3. Spleens and 11 
bone marrow were harvested upon euthanasia for MDSC isolation.   12 
 13 
Flow cytometry and cell sorting 14 
Single cell suspensions were prepared from mouse bone marrow or spleen by 15 
mechanical disruption.  Red blood cells were lysed, and the remaining leukocytes 16 
were washed with PBS, and resuspended in PBS + 2% FBS. For analysis of 17 
patient blood samples, peripheral blood mononuclear cells (PBMC) were 18 
separated using gradient centrifugation. Samples were analyzed on a 19 
FACScalibur (BD) or LSRII (BD).  Cell sorting for multiple markers was 20 
performed on a FACSAriaII (BD).  Data were analyzed using FlowJo (Treestar).  21 
 8 
Peripheral blood from previously untreated, advanced stage HNC patients was 1 
obtained with informed consent under University of Pennsylvania IRB protocol 2 
#417200 or Philadelphia VA Medical Center protocol #01090. 3 
 4 
Histology 5 
Subcutaneous tumors were fixed in buffered formalin solution, paraffin-6 
embedded and stained with hematoxylin and eosin (H&E). CD11b+Gr1+, 7 
CD11b+Gr1+CD38low, and CD11b+Gr1+CD38high cells were sorted by flow 8 
cytometry. Cytospin preparations were stained using the Hema 3 system (Fisher 9 
Scientific).  10 
 11 
T cell suppression 12 
CD11b+Gr1+, CD11b+Gr1+CD38low, and CD11b+Gr1+CD38high cell populations 13 
were sorted by flow cytometry. Antigen-specific CD8+ T cell suppression was 14 
tested as described previously (24).  15 
 16 
Ex vivo MDSC differentiation  17 
Generation of MDSCs from bone marrow has been described previously (25).  18 
Cytokine concentrations used: 0.1 ng/ml (GM-CSF and IL-4), 10 ng/ml (TNFα 19 
and IFNγ), and 100 ng/ml (IL-6, CXCL16 and IGFBP-3). HNM007 or AKR 20 
conditioned medium (CM) were used at 50% v/v. Anti-CD38 monoclonal antibody 21 
and IgG2a isotype control were used at 10ug/ml.   22 
 23 
 9 
Colony formation and cell recovery assays 1 
Isolation of MDSCs from tumor-bearing L2-cre;p120-/- mice by magnetic cell 2 
sorting was described previously (24). 200,000 cells were seeded in each 35 mm 3 
plate containing 1 ml of methylcellulose-based medium containing factors that 4 
promote growth of granulocyte-macrophage progenitors (M3534; Stem Cell 5 
Technologies).  Anti-CD38 monoclonal antibody and IgG2a isotype control were 6 
used at 10ug/mL. Colonies were counted after 7 days. For recovery assays, 7 
5x105 MDSCs were seeded in complete RPMI 1640 medium supplemented with 8 
antibodies; cells were quantified by Trypan exclusion using a Countess 9 
automated cell counter (Invitrogen).   10 
 11 
Cytokine array 12 
Media from ex vivo differentiation cultures were collected and snap-frozen after 1 13 
or 5 days of culture.  Mouse cytokine array C3 kit was used according to the 14 
manufacturer’s protocol.  Results were quantified using the ImageJ protein array 15 
analyzer and normalized to positive controls to allow for comparison of relative 16 
expression levels.   17 
 18 
ESCC/MDSC co-transplantation and anti-CD38 therapeutic study 19 
 C57BL/6J recipient mice from Jackson Labs were injected subcutaneously with 20 
a mixture of 2.5x105 syngeneic HNM007 tumor cells with either 2.5x105 CD38low 21 
or CD38hi MDSCs obtained from HNM007 tumor-bearing C57BL/6J mice. 22 
Recipient mice injected with 2.5x105 syngeneic HNM007 tumor cells alone 23 
 10 
served as controls. For antibody treatment experiments, anti-CD38 monoclonal 1 
antibody or IgG2a isotype control antibody were administered intraperitoneally 2 
every 48 hours starting on day 5 post-injection.  Measurements were taken every 3 
2-3 days once tumors became palpable.   4 
 5 
Statistical analysis 6 
The Student’s t test was used to whether there is significant difference between 7 
two experimental groups (p≤0.05 was considered statistically significant).  8 
 9 
Additional details can be found in Supplementary Materials and Methods.  10 
 11 
Results 1 
Myeloid-derived suppressor cells from tumor-bearing L2-Cre;p120f/f mice exhibit 2 
elevated CD38 expression 3 
We have previously demonstrated that MDSCs play a fundamental role in 4 
tumor initiation and progression in a spontaneous genetic mouse model of ESCC 5 
(L2-Cre;p120f/f; referred to hereafter as p120-/-) (24). Here we sought to identify 6 
genes associated with an immature myeloid phenotype that contribute to the 7 
tumor promoting activities of MDSCs, thereby providing a platform to elucidate 8 
underlying molecular mechanisms. To that end, we performed microarray 9 
analysis of splenic MDSCs from 6-8 month old tumor-bearing p120-/- mice and 10 
age-matched littermate controls (Supplementary Fig.1). Among the 964 genes 11 
showing differential expression between the two groups (Figure 1A), we identified 12 
Cd38 (ranked fifth highest among all genes tested (Supplementary Table 1))as a 13 
candidate gene of interest, as it has roles in both innate and adaptive immunity in 14 
mice and humans, including, but not limited to chemotaxis of murine and human 15 
neutrophils (26,27), early myeloid differentiation (23) and lymphoid cell activation 16 
(28). We validated enhanced Cd38 mRNA and protein expression in MDSCs 17 
from tumor-bearing mice as compared to those isolated from control mice (Fig. 18 
1B-D). We also observed increased CD38 in splenic MDSCs isolated from L2-19 
IL1β mice, a model of Barrett’s esophagus and esophageal adenocarcinoma (29) 20 
(Supplementary Fig. 2). 21 
 22 
 12 
CD38 expression correlates with ESCC progression and expansion of monocytic 1 
MDSC population 2 
To determine the kinetics of CD38 expression in MDSCs, we analyzed 3 
splenic CD11b+Gr1+ populations from non-diseased (8 weeks) and tumor-bearing 4 
(6-8 months) p120-/- mice, as well as control mice.  CD11b+Gr1+ cells were 5 
slightly more abundant in spleens of non-diseased p120-/- mice and markedly 6 
elevated in spleens of tumor-bearing p120-/- mice, compared to control mice (Fig 7 
2A). CD38 expression was markedly increased only in splenic MDSCs from 8 
tumor-bearing p120-/- mice (Fig. 2B), while a more mature subset of myeloid cells 9 
(CD11b+Gr1-) exhibited no change in CD38 levels (Fig 2B).  10 
We next tested two murine ESCC cell lines (AKR (30) and HNM007 (31)) 11 
for their ability to generate MDSCs in vivo using a syngeneic transplant model. 12 
We observed dramatically increased CD38 levels in all myeloid populations from 13 
spleens of HNM007 tumor-bearing mice, yet in AKR tumor-bearing mice CD38 14 
levels were overall lower (Fig. 2C, Supplementary Fig. 3). Interestingly, while 15 
both cell lines induced expansion of myeloid populations in spleens of tumor-16 
bearing mice, it was significantly more pronounced (p<0.0009) in HNM007 tumor-17 
bearing mice (Fig. 2D). Furthermore, we observed differences in distribution of 18 
granulocytic and monocytic MDSCs (G-MDSC and M-MDSC, respectively), as 19 
well as mature monocytes (Fig. 2D). G-MDSCs (CD11b+Ly6G+) were less 20 
abundant (p<0.02) in HNM007 tumor-bearing mice, compared to AKR. There 21 
also was a trend of M-MDSC (CD11b+Ly6C+) expansion, accompanied by a 22 
significant increase in mature monocytes (CD11b+Ly6C-Ly6G-) in HNM007, 23 
 13 
compared to AKR tumor-bearing and control mice (p<0.02). These findings 1 
suggest that CD38 may be relevant to M-MDSC expansion in tumor-bearing 2 
mice. 3 
 4 
CD38high MDSCs possess greater immunosuppressive and tumor-promoting 5 
capacity than CD38low MDSCs 6 
Since the CD38high MDSC population expands in tumor-bearing mice, we 7 
hypothesized that CD38high MDSCs possess greater immunosuppressive 8 
potential than CD38low MDSCs.  To test this, we sorted CD38high and CD38low 9 
MDSCs from HNM007 tumor-bearing mice and assessed their capacity to 10 
suppress OT-1 T cell growth following stimulation with cognate antigen.  CD38high 11 
MDSCs demonstrated significantly greater T cell suppressive capacity, compared 12 
to their CD38low counterparts (Fig. 3A), at 2:1 OT-1 to MDSC ratio, while a trend 13 
of increased suppression was observed at 1:1 and 4:1 ratios. 14 
Next we evaluated the impact of co-injection of CD38high MDSCs with 15 
HNM007 cells on tumor growth. Tumor volumes in CD38high group were 16 
significantly larger than CD38low tumors on days 6 and 10 (Fig. 3B), and larger 17 
than control HNM007 tumors on days 8, 10 and 13 (Fig. 3B). No difference in 18 
size was detected between the CD38low and control HNM007 tumors. 19 
Furthermore, CD38high-injected tumors were characterized by increased necrosis 20 
and inflammatory infiltrate, compared to controls (Fig. 3C, D). These results 21 
suggest that CD38high MDSCs may possess greater tumor-promoting capacity 22 
than CD38low MDSCs in vivo. 23 
 14 
 Next we investigated whether CD38 is required for the 1 
immunosuppressive function of MDSCs by analyzing the capacity of MDSCs 2 
from Cd38-/- and Cd38+/+ (wt) mice bearing HNM007 tumors to suppress OT-1 T 3 
cell proliferation.  Interestingly, Cd38-/- MDSCs exhibited significantly reduced 4 
immunosuppressive capacity at 1:1 and 4:1 OT-1 to MDSC ratios (Fig. 3E).  5 
 6 
CD38high MDSCs are phenotypically different from the CD38low subset 7 
Next we analyzed CD38high and CD38low splenic MDSCs from tumor-8 
bearing p120-/- mice via microarray (Supplementary Fig.4) and detected 9 
differential expression of 498 genes (Fig. 4A, Supplementary Table 2). Among 10 
genes with the greatest increase in expression, was inducible nitric oxide 11 
synthase (iNos). qPCR analysis further revealed that  iNos expression was 12 
significantly elevated in CD38high MDSCs compared to CD38low MDSCs, while 13 
expression of arginase 1 (Arg1) and NADPH oxidase subunit (Nox2) , two 14 
additional mediators of MDSC suppressive function, was comparable in the 15 
subpopulations  (Fig. 4B). iNOS protein expression was also validated in 16 
CD38high MDSCs (Fig 4C). Since iNos is a target of NFκB transactivation (32), we 17 
evaluated phospho-NFκB levels in CD38high and CD38low MDSCs and found 18 
elevated phospho-NFκB (p65) levels in the CD38high population (Fig. 4C). To test 19 
whether iNOS contributes to the increased immunosuppressive capacity of 20 
CD38high MDSCs, we used an iNOS inhibitor (L-NMMA), and found that it 21 
completely abrogated OT-1 T cell suppression mediated by CD38high MDSCs 22 
(Fig. 4D). Finally, the CD38 inhibitor AraF-NAD (33) partially rescued OT-1 T cell 23 
 15 
proliferation (Fig. 4E), suggesting that CD38 enzymatic activity is required for 1 
immunosuppressive capacity of CD38high MDSCs. Furthermore, iNOS expression 2 
was decreased in MDSCs isolated from the spleens of HNM007 tumor-bearing 3 
Cd38-/- (Fig. 4F).   4 
Morphological assessment of sorted CD38low and CD38high MDSCs 5 
revealed that the CD38high population consists of more immature cells, such as 6 
promyelocytes (~10%), myelocytes (5-10%) and metamyeloctyes (5-10%), and 7 
band cells (~70%), whereas the CD38low population consists of band cells 8 
(<10%) and mature neutrophils (>90%) (Fig. 4G), demonstrating that CD38high 9 
MDSCs are morphologically more immature than CD38low MDSCs. 10 
 11 
IFNγ, TNFα, CXCL16, IGFBP-3 and IL-6 induce CD38 expression   12 
 Since we found that MDSCs from HNM007 tumor-bearing mice have 13 
increased CD38 expression, compared to AKR tumors (Fig. 2C), we sought to 14 
understand signaling pathways underlying this phenotype.  We performed ex vivo 15 
bone marrow differentiation assays using GM-CSF, IL-4 (both required for 16 
CD11b+Gr1+ generation from bone marrow progenitors (25)) and conditioned 17 
media (CM) from either HNM007 or AKR cells. Only HNM007 CM induced CD38 18 
expression (Fig. 5A).  Since IFNγ and TNFα are key components of the pro-19 
inflammatory milieu and are known activators of CD38 transcription (34), we 20 
used these cytokines in ex vivo differentiation assays. Interestingly, both factors, 21 
individually or in combination, induced CD38 expression in CD11b+Gr1+ cells 22 
(Fig. 5A).  A cytokine array using CM from ex vivo differentiation experiments 23 
 16 
revealed several factors, including CXCL16 and IGFBP-3 that were present at 1 
higher levels in HNM007 cultures as compared to AKR cultures (Fig.5B). In 2 
addition, the pro-inflammatory cytokine IL-6, a predicted activator of CD38 3 
transcription (34), was elevated in HNM007 cultures, albeit not as dramatically as 4 
CXCL16 or IGFBP-3 (Fig. 5B).  Next we investigated the capacity of recombinant 5 
IL-6, CXCL16 and IGFBP-3 to increase CD38 expression ex vivo.  Interestingly, 6 
addition of IL-6, CXCL16 and IGFBP-3 in combination induced CD38 expression 7 
in AKR CM cultures (Fig. 5C).  8 
 9 
Cross-linking of CD38 by an agonistic antibody impairs expansion and survival of 10 
CD11b+Gr1+ cells in vitro and suppresses tumor growth in vivo 11 
 To test whether cross-linking of CD38 with a monoclonal antibody has an 12 
effect on MDSC function(s), MDSCs from spleens of tumor-bearing p120-/- mice 13 
were cultured in methylcellulose-based medium in the presence of an anti-CD38 14 
monoclonal antibody (NIM-R5) or isotype control (IgG2a).  Addition of anti-CD38 15 
antibody inhibited growth of colonies from splenic MDSCs, and the effect of anti-16 
CD38 antibody remained unchanged regardless of whether splenocytes were 17 
pre-sorted (Fig. 6A and 6B), demonstrating that the anti-CD38 antibody inhibits 18 
MDSC proliferation and survival in vitro.  In suspension culture, sorted MDSCs 19 
survive only a few days, but their survival was further reduced in the presence of 20 
anti-CD38 antibody (Fig. 6C).  We also tested whether CD38 cross-linking 21 
inhibits accumulation of CD11b+Gr1+CD38high cells ex vivo in the presence of 22 
HNM007 CM. Using an additional anti-CD38 antibody (clone 90), we observed a 23 
 17 
dose-dependent decrease in CD38 expression within the CD11b+Gr1+ population 1 
(Fig. 6D).  Given that the proportion of CD11b+Gr1+ cells within the culture 2 
remained consistent (25-30%; data not shown), these data demonstrate that the 3 
CD11b+Gr1+CD38high population is likely depleted as a result of CD38 cross-4 
linking. Lastly, anti-CD38 antibody treatment resulted in decreased tumor growth 5 
rate in vivo in a subcutaneous HNM007 transplant ESCC model as compared to 6 
isotype control (Fig. 6E). In aggregate, these data demonstrate the importance of 7 
CD38 for MDSC-mediated ESCC progression and suggest targeting CD38 as an 8 
approach to ESCC therapy. 9 
 10 
CD38 is expressed on human MDSC-like cell population that is expanded in 11 
peripheral blood of advanced-stage cancer patients 12 
 To determine whether our findings may be relevant to human cancers, we 13 
analyzed CD38 expression in the CD15hiCD33lo population of PBMCs from 14 
advanced stage head and neck cancer and non-small cell lung cancer patients 15 
and healthy donors. In contrast to our observations in mice, we found that CD38 16 
expression levels were unchanged in CD15hiCD33lo PBMCs from cancer 17 
patients, compared to healthy donors (Supplementary Fig.7). However, this 18 
population was significantly expanded from 0.5% of total PBMCs in healthy 19 
donors to up to 17% in cancer patients (Fig.7). 20 
  21 
 18 
Discussion   1 
Using spontaneous genetic and syngeneic transplant tumor models, as 2 
well as an ex vivo differentiation model, we have established for the first time that 3 
tumor-derived signals drive expansion of monocytic MDSCs by inducing CD38 4 
expression.  Expansion of the CD11b+Gr1+CD38high cell population occurs after 5 
initial splenic MDSC accumulation is evident, which likely indicates a requirement 6 
of threshold levels of tumor-derived signals for induction of CD38 by MDSCs 7 
(Fig. 5D). Interestingly, two different ESCC cell lines exhibited differential 8 
capacities to induce expansion of CD38high MDSCs, thereby suggesting that the 9 
tumor cells are responsible for promoting CD38 expression on MDSCs.  Based 10 
upon our ex vivo studies, the tumor-derived signals may act directly on immature 11 
myeloid cell populations present in hematopoietic tissues to promote CD38 12 
expression.  Furthermore, our data suggest that the tumor-derived signals do not 13 
promote enhanced proliferation of CD38high MDSCs (RB1 pathway was activated 14 
in CD38high MDSCs (Supplementary Fig. 5)), but provide these cells with 15 
increased survival potential.  16 
Herein, we demonstrate that CD38high MDSCs are halted at an earlier 17 
differentiation stage compared to CD38low MDSCs. Binding of cognate ligand by 18 
CD38 can contribute directly to the differentiation halt (23), which suggests that 19 
CD38 signaling may contribute to the maintenance of undifferentiated state 20 
observed in CD38high MDSCs.  Although CD38 has been demonstrated to bind 21 
CD31 (21), we do not know if this interaction contributes to the observed 22 
properties of CD38high MDSCs. 23 
 19 
CD38high MDSCs express elevated iNOS levels compared to CD38low 1 
MDSCs, and iNOS is required for T cell suppression by CD38high MDSCs.  2 
Interestingly, CD38 can induce iNOS upregulation in murine activated microglia 3 
(resident monocytes of the brain) (35). Furthermore, Cd38-/- mice  produce less 4 
tumor-associated microglia in a syngeneic  transplant model of glioma (36). 5 
Strikingly, we have found that in Cd38-/- mice, subcutaneous ESCC tumors 6 
induce a less pronounced expansion of M-MDSCs, regardless of the cell line 7 
used to generate tumors (Supplementary Fig. 6). These findings support the 8 
premise that CD38 promotes expansion of M-MDSCs, as well as elevated iNOS 9 
expression. We also observed increased phospho-NFκB levels in 10 
CD11b+Gr1+CD38high cells.  This is consistent with observations made in murine 11 
B cells, where CD38 ligation activates NFκB (37). Furthermore, NFκB-mediated 12 
activation of iNOS has been described in LPS-stimulated macrophages (38), 13 
highlighting the possibility that elevated phospho-NFκB levels in CD38high 14 
MDSCs may contribute to increased expression of iNOS observed in these cells.   15 
Several factors are likely to be responsible for activating CD38 expression, 16 
including IFNγ, TNFα (34), as well as IL-6, IGFBP3 and CXCL16.  We have 17 
demonstrated that IFNγ and TNFα induce bone marrow-derived CD11b+Gr1+ 18 
cells to express CD38 ex vivo.  As both IFNγ and TNFα are often produced 19 
during chronic inflammation, they may be primary inducers of CD38 expression 20 
(Fig. 5D).  In fact, TNFα inhibition can impair immunosuppressive capacity of 21 
MDSCs and induce differentiation in a murine model of chronic inflammation, 22 
while MDSCs from Tnf-/- mice have reduced iNOS levels (39).  23 
 20 
Our finding of a CXCL16 and IGFBP-3-mediated response in MDSCs has 1 
not been described previously. However, CXCL16 expression can be promoted 2 
by IFNγ and TNFα (40), the two most potent inducers of CD38 expression in our 3 
ex vivo system. Interestingly, IGFBP-3 has been shown to increase intracellular 4 
Ca2+ levels in vitro (41). Ca2+ signaling, which can be mediated by ectoenzymatic 5 
activity of CD38 (34), is important for multiple immunomodulatory processes 6 
(42,43). Therefore, it is possible that in MDSCs IGFBP-3 can be modulating Ca2+ 7 
mobilization by increasing CD38 expression.  8 
IL-6 is a major regulator of STAT3 signaling, which is essential for 9 
establishment of immunosuppressive microenvironment within the tumor (44). In 10 
MDSCs, STAT3 activation enhances production of the S100A8/A9 pro-11 
inflammatory proteins, which also contribute to maintenance of a low 12 
differentiation or immature state (45). These data are in agreement with our 13 
observation that IL-6 can promote CD38 expression on MDSCs generated ex 14 
vivo, since CD38high MDSCs are less differentiated than CD38low MDSCs (Fig. 15 
4B).   16 
Herein, we demonstrate the efficacy of anti-CD38 monoclonal antibody 17 
treatment in vitro and in vivo. Moreover, we report CD38 expression by human 18 
MDSCs; therefore, anti-CD38 therapy may represent a novel approach to 19 
targeting this immunosuppressive population in cancer treatment strategies. 20 
Furthermore, since CD38high Tregs possess enhanced suppressive potential 21 
compared to CD38low Tregs (18,19), anti-CD38 therapy may present the 22 
advantage of targeting several immunosuppressive cell types at the same time. 23 
 21 
Recently, an anti-CD38  monoclonal antibody (Daratumumab)  was shown to be 1 
efficient in treatment of multiple myeloma in pre-clinical studies (46). A similar 2 
approach may induce ablation of MDSCs in patients with advanced stage solid 3 
cancers, and thus, may be suitable as an adjuvant to conventional therapies. The 4 
expression pattern of CD38 in a broad range of cell types can raise a concern 5 
about potential adverse effects of anti-CD38 therapy (47), however, early clinical 6 
studies of Daratumumab in multiple myeloma have demonstrated an acceptable 7 
safety profile, suggesting that an appropriate dosage and treatment schedule 8 
allow for minimizing of the effects of targeting CD38 in normal tissue (48).  9 
MDSCs contribute to the T cell suppression repertoire found in cancer, 10 
which merits further investigation as a prospective therapeutic target (49).  In this 11 
study, we have identified CD38 as being suitable for potential MDSC targeting 12 
and useful in identification of potently immunosuppressive MDSC populations. 13 
Thus, anti-CD38 monoclonal antibody therapy (46) may hold potential for 14 
targeting CD38-expressing MDSCs (50) in patients with certain types of cancer.  15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 22 
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Figure 1. CD38 is significantly upregulated in CD11b+Gr1+ cells from tumor-
bearing p120-/- mice. (A) Heatmap illustrating the results of a microarray 
analysis performed using CD11b+Gr1+ cells sorted from the spleens of 6 tumor-
bearing p120-/- mice and 3 pooled samples from healthy littermate controls (n=9). 
Increased expression of the Cd38 gene and protein in CD11b+Gr1+ cells from 
tumor-bearing mice was confirmed by (B) qPCR (*p=0.007) and (C) FACS (n= 3; 
*p=0.009). (D) Frequencies of CD38+ cells (*p=0.003). 
 
Figure 2. CD38 expression increases in monocytic myeloid cells with 
disease progression. (A) Splenocytes from healthy control, non-diseased (ND) 
p120-/- and tumor-bearing (TB) p120-/- mice were analyzed by FACS for CD38 
expression on myeloid cell populations.  (B) Histograms comparing CD38-FITC 
fluorescence levels on two cell subsets from control, p120-/- non-diseased and 
p120-/- tumor-bearing mice. (C) Splenocytes from control non-diseased and AKR 
or HNM007 subcutaneous tumor-bearing C57BL/6 mice analyzed by FACS. 
Histograms compare CD38 expression levels in listed subpopulations from 
control and tumor-bearing mice. (D) Splenocytes from control and tumor-bearing 
mice were analyzed by FACS for distribution of CD11b, Ly6C, Ly6G and CD38 
antigens. Pie charts demonstrate the frequencies of lymphoid (CD11b-) and 
myeloid (CD11b+) cell populations in spleens of control and tumor-bearing mice 
with the myeloid population further broken down into Ly6C+, Ly6G+ and Ly6C-
Ly6G- subsets (n=3 per group). 
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Figure 3. CD38High MDSCs are more immunosuppressive and promote 
tumor growth more efficiently than the CD38Low MDSCs. (A) CD38high and 
CD38low MDSCs from tumor-bearing p120-/- mice were used in a T cell 
suppression assay (n=3; *p=0.0007). (B) C57BL/6 mice were injected with 
HNM007 cells in combination with MDSCs (CD38High or CD38Low) or alone (n=5 
per group).  Tumor volumes were compared between the CD38High and CD38Low 
groups (*p=0.004 and 0.03), and between CD38High and control HNM007 tumors 
(** p=0.01, 0.003 and 0.01). (C) Representative H&E and CD45 
immunohistochemistry of CD38High-injected, CD38Low or control tumors. (D) 
Tumors were scored for abundance of necrotic areas and inflammatory infiltrate 
on the scale 0-4. (E) Splenic MDSCs from HNM007 tumor-bearing Cd38-/- or wt 
mice were used in a T cell suppression assay (*p=0.003 and 0.04).  
 
Figure 4. CD38High MDSCs are phenotypically different from the CD38Low 
subset. (A) Heatmap illustrating the results of a microarray analysis performed 
using CD38High and CD38Low CD11b+Gr1+ cells sorted from spleens of 4 tumor-
bearing p120-/- mice. (B) qPCR analysis of iNos, Arg1 and Nox2 gene expression 
(*p=9x10-8). (C) Western blot analysis of iNOS and phospho-NFκB protein levels 
in CD38High and CD38Low MDSCs. (D) iNOS inhibitor (L-NMMA) and (E)CD38 
inhibitor (AraF-NAD) were tested in a T cell suppression assay (*p=0.004 and 
0.04, respectively). (F) Expression levels of iNOS in splenic MDSCs from tumor-
bearing Cd38-/- or wt mice were assessed by FACS. (G) Cytospin preparations 
from CD38high and CD38Low MDSCs. 
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Figure 5. IFNγ, TNFα, IGFBP-3, CXCL16 and IL-6 induce CD38 expression 
and impair myeloid cell differentiation. (A) CD38 expression in CD11b+Gr1+ 
cells from ex vivo differentiation cultures was tested by FACS.  Results are 
presented as mean fluorescence intensity (MFI) (n=3; * p≤0.0001, **p=2.5x10-5). 
(B) Cytokine array performed with media from ex vivo differentiation cultures (24 
or 120-hour). Each cytokine tested in duplicate. Difference in normalized 
expression between HNM007 and AKR groups is shown.  (C) Ex vivo 
differentiation as in (A) with the addition of cytokines to the AKR conditioned 
media (n=3; *p<0.05, ** p<0.005). (E) In mice, early stages of cancer initiation 
and progression lead to MDSC expansion. Tumor progression leads to amplified 
signals (such as cytokines) reaching MDSCs, which induces a differentiation halt 
and expansion of CD38High monocytic MDSCs with enhanced 
immunosuppressive capacity (mediated by iNOS, which produces nitric oxide 
(NO)).  
 
Figure 6. Cross-linking of CD38 by an agonistic antibody impairs expansion 
and survival of CD11b+Gr1+ cells in vitro and suppresses tumor growth in 
vivo. (A) Representative images from methylcellulose cultures of CD11b+Gr1+ 
cells treated with anti-CD38 monoclonal antibody (NIMR-5) or isotype control 
(IgG2a), after 5 days of culture. (B) Number of colonies formed following 7 days 
of culture (n=3; *p=4x10-5).  (C) CD11b+Gr1+ cells were cultured in RPMI with 
anti-CD38 or isotype control antibody, and counted at indicated time points. (n=6 
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per group; *p<5x10-7, **p<2x10-7, ***p<0.0005). (D) Ex vivo differentiation 
performed with HNM007 conditioned medium and anti-CD38 agonist (NIM-R5) or 
isotype control (IgG2a) antibody. CD38 expression (using the clone 90 antibody) 
on the surface of CD45+7-AAD-CD11b+Gr1+ was measured by FACS (n=3 per 
group; * p<0.003, ** p<0.0005). (E) HNM007 tumor growth kinetics in C57BL/6 
mice treated with anti-CD38 (NIM-R5) or isotype control (IgG2a) antibody (start 
of treatment is marked by an arrow, n=6 per group; *p=0.005, 0.005 and 0.04). 
 
Figure 7. CD38+ MDSC-like population is expanded in the peripheral blood 
of advanced-stage cancer patients. Histograms depict frequencies of 
CD38+CD15highCD33low cells in peripheral blood mononuclear cells (PBMC) from 
head and neck (HNC) and non-small cell lung (NSCLC) cancer patients and 
healthy donors. 
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